Back to Search Start Over

Retrospective review of antimicrobial use for gastroschisis patients in Kigali, Rwanda: can improved stewardship reduce late inpatient deaths?

Authors :
Diehl, Thomas M.
Davis, James R.
Nsengiyumva, Alice
Igiraneza, Deborah
Hong, Philip
Umutoni, Rosine
Neal, Dan
Ndibanje, Alain Jules
Bunogerane, Gisèle Juru
Petroze, Robin T.
Ntaganda, Edmond
Source :
European Journal of Pediatrics. Jul2023, Vol. 182 Issue 7, p3203-3209. 7p. 3 Charts.
Publication Year :
2023

Abstract

Gastroschisis mortality is 75–100% in low-resource settings. In Rwanda, late deaths are often due to sepsis. We aimed to understand the effect of antimicrobial use on survival. We conducted a retrospective review of gastroschisis patients at a tertiary hospital in Kigali, Rwanda between January 2016–June 2019. Demographics, antimicrobial use, microbiology, and outcomes were abstracted. Descriptive and univariate analyses were conducted to assess factors associated with improved survival. Among 92 gastroschisis patients, mortality was 77%(n = 71); 23%(n = 21) died within 48 h. 98%(n = 90) of patients received antibiotics on arrival. Positive blood cultures were obtained in 41%(n = 38). Patients spent 86%(SD = 20%) of their hospital stay on antibiotics and 38%(n = 35) received second-line agents. There was no difference in age at arrival, birth weight, gestational age, silo complications, or antimicrobial selection between survivors and non-survivors. Late death patients spent more total hospital days and post-abdominal closure days on antibiotics (p < 0.001) compared to survivors. There was no difference in the proportion of hospital stay on second-line antibiotics (p = 0.1). Conclusion: We identified frequent late deaths, prolonged antibiotic courses, and regular use of second-line antibiotic agents in this retrospective cohort of Rwandan gastroschisis patients. Future studies are needed to evaluate antimicrobial resistance in pediatric surgical patients in Rwanda. What is Known: • Global disparities in gastroschisis outcomes are extreme, with <4% mortality in high-income settings and 75-100% mortality in low-income settings. • Antimicrobial surveillance data is sparse across Africa, but existing evidence suggests high levels of resistance to first-line antibiotics in Rwanda. What is New: • In-hospital survival for gastroschisis was 23% from 2016-2019 and most deaths occurred late (>48hrs after admission) due to sepsis. • Rwandan gastroschisis patients received prolonged courses of antibiotics and second-line antibiotics were frequently used without culture data, raising concern for antimicrobial resistance. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03406199
Volume :
182
Issue :
7
Database :
Academic Search Index
Journal :
European Journal of Pediatrics
Publication Type :
Academic Journal
Accession number :
164982150
Full Text :
https://doi.org/10.1007/s00431-023-04955-9